LTR Pharma
CompanyAustralia
LTR Pharma develops one asset. Mostly small molecule acting on PDE5A; based in Australia.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 1
- Signal
Pipeline
1Inhibits phosphodiesterase 5, enhancing nitric oxide-mediated blood flow to support erections.
Stage not known, Small molecule, PDE5A
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1
- Similar companies1